{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05753059",
            "orgStudyIdInfo": {
                "id": "2000034315"
            },
            "secondaryIdInfos": [
                {
                    "id": "1R01DK130997-01",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/1R01DK130997-01"
                }
            ],
            "organization": {
                "fullName": "Yale University",
                "class": "OTHER"
            },
            "briefTitle": "Mechanisms of Diuretic Resistance in Heart Failure, Aim 2",
            "officialTitle": "Mechanisms of Diuretic Resistance in Heart Failure, Aim 2",
            "acronym": "MsDR 2",
            "therapeuticArea": [
                "Cardiovascular"
            ],
            "study": "mechanisms-of-diuretic-resistance-in-heart-failure-aim"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-08-10",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-02-21",
            "studyFirstSubmitQcDate": "2023-02-21",
            "studyFirstPostDateStruct": {
                "date": "2023-03-03",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-02",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-04",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Jeffrey Testani",
                "investigatorTitle": "Associate Professor of Medicine",
                "investigatorAffiliation": "Yale University"
            },
            "leadSponsor": {
                "name": "Yale University",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "Randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide.",
            "detailedDescription": "This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide.\n\nPatients will be co-enrolled in this study and an ancillary study for administration of Bendroflumethiazide. Administration of bendroflumethiazide will take place under an ancillary protocol."
        },
        "conditionsModule": {
            "conditions": [
                "Heart Failure"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "CROSSOVER",
                "interventionModelDescription": "Randomized placebo-controlled, double-blind, double-dummy, crossover design",
                "primaryPurpose": "OTHER",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 50,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Placebo/ Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "Placebo/ Amiloride",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21",
                    "interventionNames": [
                        "Drug: Placebo",
                        "Drug: Amiloride"
                    ]
                },
                {
                    "label": "Placebo/ Bendroflumethiazide",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21",
                    "interventionNames": [
                        "Drug: Placebo",
                        "Drug: Bendroflumethiazide"
                    ]
                },
                {
                    "label": "Bendroflumethiazide/ Amiloride",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21",
                    "interventionNames": [
                        "Drug: Amiloride",
                        "Drug: Bendroflumethiazide"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, added to bumetanide on Days 0, 7, 14 and 21",
                    "armGroupLabels": [
                        "Placebo/ Amiloride",
                        "Placebo/ Bendroflumethiazide",
                        "Placebo/ Placebo"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Amiloride",
                    "description": "This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21",
                    "armGroupLabels": [
                        "Bendroflumethiazide/ Amiloride",
                        "Placebo/ Amiloride"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Bendroflumethiazide",
                    "description": "This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of bendroflumethiazide/placebo and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21",
                    "armGroupLabels": [
                        "Bendroflumethiazide/ Amiloride",
                        "Placebo/ Bendroflumethiazide"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in peak FENa from bumetanide monotherapy to bumetanide plus combination therapy",
                    "description": "Change in peak FENa from bumetanide monotherapy to bumetanide plus combination therapy",
                    "timeFrame": "21 days"
                },
                {
                    "measure": "Change in distal sodium reabsorption",
                    "description": "Change in distal sodium reabsorption (FELi minus FENa) from bumetanide monotherapy to bumetanide plus combination therapy",
                    "timeFrame": "21 days"
                },
                {
                    "measure": "Correlation between distal sodium reabsorption and uEV pendrin/CD9",
                    "description": "Correlation between distal sodium reabsorption (FELi minus FENa) and uEV pendrin/CD9",
                    "timeFrame": "21 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Chronic clinical diagnosis of HF with a documented ejection fraction \\<40%.\n2. Use of beta blocker, ACE, ARB or neprilysin inhibitor (sacubitril/valsartan), aldosterone antagonist, and SGLT2 inhibitor at \u226550% guideline directed doses for 30 days with no plan for titration/change during the study period.\n3. Chronic stable use of \u226580mg furosemide equivalents per day for \u2265 30 days\n4. Peak FENa \\< 5% following 10mg IV bumetanide challenge at the screening visit\n5. Absence of hospitalizations in the previous 3 months.\n6. At optimal volume status by symptoms, exam, and dry weight.\n7. Serum potassium \u2264 5.0 mmol/L\n8. Serum sodium \u2265 130 mEq/L\n9. Age \\> 18 years\n\nExclusion Criteria:\n\n1. GFR \\<20 ml/min/1.73m2\n2. Use of any non-loop type diuretic in the last 14 days with the exclusion of low dose aldosterone antagonist (e.g., spironolactone \u226450 mg)\n3. History of flash pulmonary edema or a \"brittle\" volume sensitive HF phenotype such as amyloid cardiomyopathy\n4. Hemoglobin \\< 8 g/dL\n5. Pregnant or breastfeeding\n6. Inability to give written informed consent or comply with study protocol or follow-up visits",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Veena Rao",
                    "role": "CONTACT",
                    "phone": "203-737-3571",
                    "email": "veena.s.rao@yale.edu"
                },
                {
                    "name": "Kara Otis",
                    "role": "CONTACT",
                    "phone": "203-737-3571",
                    "email": "kara.otis@yale.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Jeffrey Testani",
                    "affiliation": "Yale University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Yale University",
                    "status": "RECRUITING",
                    "city": "New Haven",
                    "state": "Connecticut",
                    "zip": "06510",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Katherine Keith",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.30815,
                        "lon": -72.92816
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006333",
                    "term": "Heart Failure"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006331",
                    "term": "Heart Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9421",
                    "name": "Heart Failure",
                    "asFound": "Heart Failure",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9419",
                    "name": "Heart Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001539",
                    "term": "Bendroflumethiazide"
                },
                {
                    "id": "D000000584",
                    "term": "Amiloride"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004232",
                    "term": "Diuretics"
                },
                {
                    "id": "D000045283",
                    "term": "Natriuretic Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000062646",
                    "term": "Acid Sensing Ion Channel Blockers"
                },
                {
                    "id": "D000026941",
                    "term": "Sodium Channel Blockers"
                },
                {
                    "id": "D000049990",
                    "term": "Membrane Transport Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000062686",
                    "term": "Epithelial Sodium Channel Blockers"
                },
                {
                    "id": "D000062865",
                    "term": "Diuretics, Potassium Sparing"
                },
                {
                    "id": "D000000959",
                    "term": "Antihypertensive Agents"
                },
                {
                    "id": "D000049993",
                    "term": "Sodium Chloride Symporter Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7411",
                    "name": "Diuretics",
                    "relevance": "LOW"
                },
                {
                    "id": "M5306",
                    "name": "Bumetanide",
                    "relevance": "LOW"
                },
                {
                    "id": "M3925",
                    "name": "Amiloride",
                    "asFound": "Pillow",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4830",
                    "name": "Bendroflumethiazide",
                    "asFound": "Cubital Tunnel",
                    "relevance": "HIGH"
                },
                {
                    "id": "M23177",
                    "name": "Sodium Channel Blockers",
                    "relevance": "LOW"
                },
                {
                    "id": "M30025",
                    "name": "Diuretics, Potassium Sparing",
                    "relevance": "LOW"
                },
                {
                    "id": "M4277",
                    "name": "Antihypertensive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M26152",
                    "name": "Sodium Chloride Symporter Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "NaAg",
                    "name": "Natriuretic Agents"
                },
                {
                    "abbrev": "ChanBlk",
                    "name": "Channel Blockers"
                },
                {
                    "abbrev": "AnAg",
                    "name": "Antihypertensive Agents"
                }
            ]
        }
    },
    "hasResults": false
}